Related Experiment Video
Updated: Jun 24, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Metformin suppresses high glucose-induced poly(adenosine diphosphate-ribose) polymerase overactivation in aortic
Meriem Mahrouf-Yorgov1, Nicolas Marie, Didier Borderie
1EA 3617 Biochimie radicalaire et atteintes vasculaires, Université Paris Descartes, UFR des Sciences Pharmaceutiques et Biologiques, 4, avenue de l'Observatoire, F75006 Paris, France.
Abstract:
Overactivation of poly(adenosine diphosphate-ribose) polymerase (PARP), an enzyme involved in cellular response to DNA injury resulting from oxidative and nitrosative stress, is considered to play a key role in the pathogenesis of diabetes complications by promoting numerous vascular dysfunctions. In this study, we examined the ability of metformin, which was reported to possess intrinsic vasculoprotective properties independently of its antihyperglycemic effects, to inhibit PARP activation induced by high glucose concentrations in bovine aortic endothelial cells; and we investigated the potential mechanisms involved in this inhibition. The PARP activity was measured by cellular enzyme-linked immuno-specific assay (CELISA) method; cell poly(ribosyl)ated protein polymer accumulation was evaluated by immunofluorescence. Peroxynitrite anion productions were determined using dihydrorhodamine 123 fluoroprobe; and expression of p47phox subunit of nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidase was analyzed by Western blot in the absence and presence of protein kinase C and NAD(P)H oxidase inhibitors (calphostin and diphenyleneiodonium chloride, respectively). Our data showed that a therapeutically relevant concentration of metformin (5.10(-5) mol/L) was able to abolish PARP activation, to reduce poly(ribosyl)ated protein polymer accumulation, to decrease intracellular peroxynitrite anion level, and to reverse the overexpression of p47phox in bovine aortic endothelial cells stimulated by 25 mmol/L glucose in a similar manner to that of calphostin or diphenyleneiodonium chloride. Taken together, these results suggest that metformin could inhibit glucose-induced PARP activation through blockade of a protein kinase C-dependent NAD(P)H oxidase activation pathway. We propose that some of the beneficial effects of metformin on vascular endothelial cell functions in diabetes may be related to its inhibitory effect on PARP overactivation and its deleterious consequences.
Insights
Metformin inhibits overactivation of poly(adenosine diphosphate-ribose) polymerase (PARP) in high glucose conditions. This mechanism involves blocking protein kinase C-dependent NAD(P)H oxidase activation, potentially explaining metformin
Area of Science:
- Endocrinology and Metabolism
- Vascular Biology
- Biochemistry
Background:
- Poly(adenosine diphosphate-ribose) polymerase (PARP) overactivation contributes to diabetes complications via vascular dysfunction.
- Metformin exhibits vasculoprotective effects independent of its glucose-lowering action.
Purpose of the Study:
- To investigate metformin's ability to inhibit high glucose-induced PARP activation in endothelial cells.
- To elucidate the mechanisms underlying metformin's inhibitory effect on PARP.
Main Methods:
- Assessed PARP activity using the CELISA method.
- Evaluated poly(ribosyl)ated protein polymer accumulation via immunofluorescence.
- Measured peroxynitrite anion production and p47phox subunit expression (NAD(P)H oxidase).
Main Results:
- Metformin (5.10(-5) mol/L) abolished PARP activation and reduced poly(ribosyl)ated protein accumulation.
- Metformin decreased intracellular peroxynitrite levels and reversed p47phox overexpression.
- These effects were comparable to those of protein kinase C and NAD(P)H oxidase inhibitors.
Conclusions:
- Metformin inhibits glucose-induced PARP activation by blocking a protein kinase C-dependent NAD(P)H oxidase pathway.
- Metformin's vascular benefits in diabetes may stem from inhibiting PARP overactivation.
- This study provides mechanistic insight into metformin's vasculoprotective properties.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Cell Specific Gene Expression
GPCRs Regulate Adenylyl Cylase Activity
Two...
cAMP-dependent Protein Kinase Pathways
